Fierce Pharma: the top 7 pharmaceutical companies with the largest number of layoffs in 2014

Source: Biovalley, April 7, 2015, fiercepharma, a well-known biomedical website, recently made statistics on the layoffs of global pharmaceutical giants in 2014 The data shows that compared with the past few years, the total number of layoffs in 2014 has dropped significantly In 2011-2013, the world's top 10 pharmaceutical giants cut an average of 30000 jobs a year, while in 2014, the total number of layoffs was far less In fact, the total number of layoffs of the seven pharmaceutical giants in this year was only 10691 According to the analysis, in the past few years, the pharmaceutical giants' layoffs were due to financial factors, patent cliff and clinical project failure In the past 2014, asset restructuring and M & A transactions have become the main factors of layoffs 2014 is a year of upsurge of M & A in the field of medicine During the year, atvis acquired forest lab for $25 billion in February and Allergan for $66 billion in November The three giants, Novartis GlaxoSmithKline Lilly, also moved their assets in this year Novartis bought oncology assets from GlaxoSmithKline, and sold the vaccine business to GlaxoSmithKline The two sides later established a consumer health joint venture At the same time, Novartis also sold its animal health department to Lilly Other pharmaceutical giants, including Roche, have also made small acquisitions With these transactions, the total number of buyer employees increases, but layoffs are often needed to eliminate overlapping positions and help pay for transactions While the total number of employees of the seller decreased, at the same time, it also lost some income The problem is that while pharmaceutical companies seem to focus more on asset restructuring and M & A transactions than layoffs last year, the total net staff of many pharmaceutical companies is bound to change dramatically in the next few years Source: the largest biopharma layoffs of 2014